key: cord-0697545-q783t6kh
authors: Nair, Abhijit
title: 2-deoxy-d-glucose therapy for preventing inflammatory cascade in COVID19 patients
date: 2021-09-02
journal: Saudi J Anaesth
DOI: 10.4103/sja.sja_419_21
sha: e57d44a971888c98205b666631d8fccac7c50896
doc_id: 697545
cord_uid: q783t6kh

nan

To the Editor,

Researchers have proved beyond doubt that uncontrolled blood sugars in known diabetic patients or patients without diabetes presenting with increased, uncontrolled sugars due to systemic inflammation status per se face adverse outcomes if they have COVID19 disease, due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). [1] It has been demonstrated that when human monocytes in patients with COVID19 infection were exposed to high glucose, there was exaggerated viral replication, upregulation of angiotensin-converting enzyme 2 (ACE2), and an increased cytokine production which compromised T-cell response and its overall function in curtailing underlying infection. This led to further damage to lung parenchymal cells which could explain the exaggerated virulence in diabetic patients and in patients with high blood sugars. [2] This leads to the release of proinflammatory cytokines like TNF-α, IL-1β, and IL-6 thus facilitating cytokine storm. This cytokine storm occurs in certain categories of patients due to the hyperactivation of the innate immune system by SARS-CoV-2 and excessive release of proinflammatory cytokines and chemokines.

Otto Warburg described the Warburg effect or the aerobic glycolysis in the year 1920 in which cancer cells utilize excessive glucose levels in presence of oxygen to produce lactate. [3] Researchers had earlier demonstrated in the previous pandemic that in MERS-CoV disease there was aerobic glycolysis which led to the release of proinflammatory cytokines and worsening of the disease. The same is being postulated in COVID19 disease as well. It was observed that by inhibition of glycolysis by using 2-deoxy-d-glucose, glycolytic enzymes 6-phospho -fructo -2-kinase/ fructose-2,6-bisphosphatase-3 (PFKFB3) which regulated phosphofructokinase-1 (PFK1) and also lactate dehydrogenase A (LDH-A) abolished viral replication and excessive cytokine release.

Glucose homeostasis is impaired in patients with diabetes mellitus, de novo patients, and also in any patient with systemic inflammatory response syndrome due to any bacterial or viral infection. Aerobic glycolysis causes hyperactivation of M1 macrophages that eventually leads to the recruitment of monocytes, neutrophils, and platelets from circulating blood. This leads to the formation of neutrophil extracellular traps and monocyte-platelet aggregates which is supposedly the reason for thrombosis. As accelerated glycolysis is possibly responsible for excessive viral replication and exaggerated severity of the disease, researchers explored agents which could inhibit glycolysis and thus potentially interfere with viral replication during the early stage of the disease. [4] In underlying viral infection, there is a shift from oxidative phosphorylation to aerobic glycolysis in the host cells which facilitates viral replication. Hypoxia-inducible factor-1α (HIF-1α) has been implicated to be an important regulator of glycolysis. HIF-1α levels are induced in SARS-CoV-2 infected monocytes. HIF-1α stabilization or inhibition has important therapeutic effects like reduced replication, reduced release of inflammatory cytokines, restores T-cell function, and improved lung epithelial cell survival [ Figure 1 ]. [5] 2-deoxy-d-glucose is a glucose molecule in wherein the 2-hydroxyl group is replaced by hydrogen as a result of which it cannot undergo further glycolysis [ Figure 1a ]. When administered systemically, it competitively inhibits the production of glucose-6-phosphate from glucose at the phosphorglucoisomerase level i.e., at step 2 of glycolysis. [6] It was observed that by inhibition of glycolysis by using 2-deoxy-d-glucose, glycolytic enzymes 6-phospho-fructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) which regulated phosphofructokinase-1 (PFK1) and also lactate dehydrogenase A (LDH-A) abolished viral replication and excessive cytokine release.

The beneficial effects of 2-deoxy-d-glucose are owing to its anti-glycolytic properties, anti-inflammatory, immune-enhancing properties which can have beneficial effects when used in the acute phase of illness. The immunomodulation properties of 2-deoxy-d-glucose is due to its ability to restore CD/ CD8 ratio, enhancing natural killer cells properties, and IFN λ levels. [7] When used in cancer patients, rapid metabolism and short half-life were the problems encountered with the use of 2-deoxy-d-glucose. Safety and efficacy in cardiac, renal, and hepatic ailments has not been validated yet. Fatigue, sweating, dizziness, nausea, symptoms of hypoglycemia are the problems of using 2-deoxy-d-glucose. To address these issues, researchers developed analogues and prodrugs of 2-deoxy-d-glucose. They are 2-halogen substituted d-glucose, fluoro-hexose compounds, and acetates of 2-deoxy monosaccharides as prodrugs. However, these compounds have been used in cancer patients and not in COVID19 patients. [8] To conclude, providing 2-deoxy-d-glucose as a substrate for inhibiting glycolysis which is a key step in disease progression could have several beneficial effects in patients with COVID19 disease. However, this adjunct therapy needs to validated by conduction well-designed, adequately powered studies. Although the adjunct although appears safe, there is no clarity regarding the dose, timing, and duration of 2-deoxy-d-glucose therapy in COVID19 patients.

Nil.

There are no conflicts of interest. 

COVID-19 and diabetes mellitus: From pathophysiology to clinical management

Targeting glucose metabolism for treatment of COVID-19

The Warburg effect: 80 years on

Diabetes is a risk factor for the progression and prognosis of COVID-19

Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis

Could targeting immunometabolism be a way to control the burden of COVID-19 infection?

Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-d-glucose and radiation: Implications for tumor therapy

2-deoxy-d-glucose and its analogs: From diagnostic to therapeutic agents

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. Fixed dilated pupils following laparoscopic urological procedure: Steep trendelenburg position was the cause For doing laparoscopic lower abdominal surgery, the Trendelenburg position of patient is required for adequate surgical exposure. In the Trendelenburg position, the patient's feet are kept 15 to 30 degrees higher than the patient's head. [1] Many surgeons do the surgery with Trendelenburg position of 30 to 45 degrees, particularly during laparoscopic and robotic surgery. The benefit of the Trendelenburg position is that the abdominal viscera move upwards, which improves visibility and surgical access to the abdominal and pelvic organs.However, this position has its own limitations, as it increases intracranial tension (ICT), intraocular pressure (IOP) and postoperative vision loss. [2] Ischemic optic neuropathy is the most common cause of postoperative vision loss. [2] Periorbital swelling and venous congestion resulting from the Trendelenburg position can lead to a compartment syndrome in the orbital space that compromises blood flow to the eye, retina, and optic nerve. [3] The optic nerve sheath diameter is a simple, safe, non-invasive, reliable monitoring of intracranial pressure. [4] Here we describe a case of elective laparoscopic vesicovaginal fistula repair, which was carried out under general anaesthesia. A 37-year-old female ASA grade I weighing 60 kg investigation CBC, kidney function test, liver function test, ECG and CXR were within normal limits. Written and informed consent was taken. In the operating room standard American society of Anesthesiologists monitor were applied. Patient was induced with Fentanyl (2 µg/kg), Propofol (2 mg/kg), Vecuronium (6 mg) and intubation was done with size 7.5 standard endotracheal tube, under direct laryngoscopy. Anaesthesia was maintained with 50% O 2 , 50% Air and Isoflurane. Increase in Heart rate and MAP >20%